PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26021F0040Treprostinil 0.6mg ML — United Therapeutics Corp

United Therapeutics Corp holds $3.8M across 190 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79720D0104. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

United Therapeutics Corp

Recipient

Sep 30, 2021

PoP end

$1K

Obligated

$152K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs United Therapeutics Corp — $90

Contract facts

Federal

Contract number36C26021F0040

Also listed as36C260-21-F-0040

Also listed as36F79720D0104-36C26021F0040

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentUnited Therapeutics Corp

CAGE3P7X8

UEIKK5FBFA43JS7

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0104

Place of performanceSILVER SPRING MD

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2020

PoP end (current)Sep 30, 2021

Obligated$1K

Current value$152K

Potential value$152K

TREPROSTINIL 0.6MG/ML is a federal award for 260-Network Contract Office 20 (36C260) held by United Therapeutics Corp. Estimated value $152K ($1K obligated). Current period of performance ends Sep 30, 2021. Last award drew 1 bidder. Place of performance: SILVER SPRING MD.

Recompete timing

Public

● Past PoP end (1786 days ago)

Current PoP ended Sep 30, 2021 (1786 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

United Therapeutics Corp — $3.8M obligated across 190 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($3.8M) · all agencies

Department of Veterans Affairs (VA)$3.7M · 97%Department of Justice (DOJ)$118K · 3%

Open full company profile →

Related awards

Same parent · incumbent

36C26026F0064

TYVASO KITS & CARTRIDGES

$379K

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26021F0040?

36C26021F0040 (Treprostinil 0.6mg ML) is a 260-Network Contract Office 20 (36C260) award with a potential value of $152K, currently held by United Therapeutics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-21-F-0040?

36C260-21-F-0040 is the dashed form of PIID 36C26021F0040 (Treprostinil 0.6mg ML), held by United Therapeutics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26021F0040?

260-Network Contract Office 20 (36C260) awarded 36C26021F0040 to United Therapeutics Corp (potential $152K).

Who is the incumbent on 36C26021F0040?

United Therapeutics Corp is the incumbent with $3.8M across 190 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2021.

When does United Therapeutics Corp’s 36C26021F0040 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action Sep 7, 2021